Klaviyo Q3: 25% Growth and Raised Forecast, but Core Debates Unresolved

What happened

Klaviyo's Q3 fiscal 2026 revenue grew 25% year over year, a slight deceleration from Q1's 28%, and management raised its full-year forecast, citing enterprise expansion and increased adoption of AI tools. The raise aligns with the base-case scenario in our master report, which expected low-20s growth and operating leverage to support a rerating, but the news provides no detail on the magnitude of the increase or any accompanying margin changes. Notably, the update omits net revenue retention and profitability figures, leaving unresolved whether the growth is translating into value per share, especially given the $42.7 million quarterly stock-based compensation hurdle. The emphasis on AI adoption is double-edged: it validates the product strategy but also raises the specter of higher compliance costs now that the Colorado and EU AI Act deadlines have passed. Overall, this is a mildly positive confirmation of revenue durability that does not alter our 'POTENTIAL BUY' rating or the $17 base-case value.

Implication

Investors should treat the Q3 revenue raise as a confirmation that the company’s growth engine is durable, but it does not change the stock’s valuation setup because the market already prices in low-20s growth and the raise lacks granularity on profitability. The next 6–9 months still hinge on whether net revenue retention holds at or above 110% and whether non-GAAP operating margin remains in the 14.5%–15.0% range despite AI investment and regulatory compliance costs. Given the passing of the June and August 2026 AI regulatory deadlines, the upcoming 10-Q for Q3 should reveal whether compliance spending accelerated and whether the raised revenue forecast was accompanied by a maintained or improved margin outlook. Until management quantifies the buyback program’s net effect on share count after the 10b5-1 plan expiration in May 2026, the per-share compounding argument remains unproven, and the stock may continue to trade on sentiment rather than fundamentals. Consequently, we maintain the 'POTENTIAL BUY' rating but would not add aggressively above $14–15 without seeing evidence of margin expansion and share count reduction in the next filing.

Thesis delta

The Q3 report provides incremental confirmation that revenue growth remains resilient at 25% and that management is confident enough to raise full-year guidance, slightly increasing the probability of the base case. However, the absence of profitability and retention data means the core uncertainties around margin durability and buyback effectiveness are unchanged. No change to the 'POTENTIAL BUY' rating; the attractive entry remains near $13.50, and we await Q3 10-Q details before adjusting valuation scenarios.